Actively Recruiting
Monitoring Minimal Residual Disease in Colorectal Cancer Patients Using Circulating Tumor DNA Analysis by ddPCR
Led by Masaryk Memorial Cancer Institute · Updated on 2026-10-28
60
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of free circulating tumor DNA ctDNA from blood, called liquid biopsy, to monitor minimal residual disease MRD in patients with colorectal cancer stages II to IV. The study aims to detect early signs of disease relapse or progression by tracking specific KRAS gene mutations G12 and G13 using a method called ddPCR. This approach could help improve how doctors predict patient outcomes and monitor treatment response after primary therapy. Participants with colorectal cancer undergo routine blood draws for ctDNA analysis at specific times depending on their cancer stage. For stage II and III patients, blood samples are collected at least 2 weeks after surgery before starting further therapy or follow-up, then every 3 months for up to 2 years. For stage IV patients, samples are taken before and at least 2 weeks after surgery or local treatment of metastases, followed by 3-month interval collections over 2 years. This observational procedure is focused on detecting recurrence and better risk stratification. During the study, participants provide blood samples regularly for ctDNA testing to detect KRAS mutations. Researchers monitor the ctDNA detection rate for MRD assessment over a 24-month period. The study involves standard care and routine follow-up visits, with no therapeutic interventions beyond blood sampling. Participants adherence to scheduled blood draws and follow-ups supports the evaluation of ctDNA as a biomarker for early recurrence detection and disease monitoring.
CONDITIONS
Brief Title
MRD Monitoring in Colorectal Cancer Using ctDNA
Research Team
I
Igor Kiss, doc. MUDr. Ph.D., MBA
M
Martin Lojová, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here